SomaLogic and NEC announce the release of SomaSuite, a professional software tool that simplifies the analysis of proteomic data generated by SomaLogic's SOMAscan assay technology. The tool enables researchers to quickly discover significant protein expression changes in their biological samples.
Researchers from SomaLogic and the University of Washington identified 36 proteins with significant expression changes in lung cancer tissue samples, including 13 new biomarkers. This study provides new insights into NSCLC biology and suggests potential therapeutic targets.
The SOMAscan assay identifies and measures thousands of proteins, unlocking protein biomarker discovery for therapeutic and diagnostic applications. This technology empowers personalized medicine by detecting early disease onset in real-time.
SomaLogic will develop a low-cost diagnostic tool using its proteomic technology to detect TB biomarkers. The grant aims to improve identification of active TB cases in developing countries.
Researchers at SomaLogic describe a breakthrough technology that detects biomarkers for lung cancer in its early stages, revealing the presence of a panel of 12 proteins. The SOMAmer technology enables accurate detection and measurement of proteins in just a few drops of blood.